<DOC>
	<DOCNO>NCT02405013</DOCNO>
	<brief_summary>Primary Objective : To evaluate efficacy ( sustained virological response 12 week end-of-treatment [ SVR12 ] ) 12-week course interferon-free regimen combine sofosbuvir weight-dosed ribavirin ( genotype 2 ) , sofosbuvir ledipasvir ( genotype 1 4 ) treatment-naïve patient infected HCV genotype 1 , 2 4 West Central Africa Secondary Objectives : 1 . To estimate study treatment SVR24 rate 2 . To evaluate clinical biological tolerance study treatment 3 . To describe HCV kinetics HCV treatment , identify associate factor 4 . To describe evolution HIV disease HCV treatment HVC-HIV co-infected patient 5 . To describe change liver fibrosis base non-invasive test treatment initiation , week 24 , week 36 treatment , estimate association SVR12 SVR24 6 . To identify factor associate SVR12 SVR24 ( include HIV status ) 7 . To evaluate performance nanodevice rapid diagnosis HCV viral load genotypying assess response treatment ( SVR12 SVR24 ) 8 . Facilitate detection treatment infect HCV support national initiative access strategy without interferon 9 . To set HCV clinical research network across French English-speaking African country , able run large-scale comparative randomize clinical trial near future .</brief_summary>
	<brief_title>Feasibility , Tolerance Efficacy Interferon-free , Antiviral Treatment With Sofosbuvir + Ribavirin Treatment Genotype 2 Sofosbuvir/Ledipasvir Treatment Genotype 1 4 Hepatitis C Virus-infected Patients West Central Africa</brief_title>
	<detailed_description>Study design Multicenter , phase IIb , non randomize , open-label trial involve 3 group HCV-mono infect HCV-HIV co-infected patient : group G1 ( patient infect HCV genotype 1 ) , group G2 ( patient infect HCV genotype 2 ) , group G4 ( patient infect HCV genotype 4 ) . Number Subjects A sample size 40 patient per group allow demonstrate SVR12 &gt; 70 % ( `` expect efficacy '' difficult-to-treat patient , accord SPARE interim result ) , low bound confidence interval &gt; 50 % ( `` unacceptable '' efficacy ) . The overall sample size 3x40=120 patient . Participating Countries 3 country West Africa ( Senegal , Côte d'Ivoire ) Central Africa ( Cameroon ) Number Sites 5 clinical site : - Côte d'Ivoire : Hepatology Departementat Yopougon University Teaching Hospital , , Abidjan ; Blood Donors clinic ( CMSDS ) National Blood Bank ( CNTS ) , Abidjan - Senegal : CRCF ( Centre Régional de Recherche et de Formation ) , Fann University Teaching Hospital - Cameroon : Clinique de la Cathédrale Duration Recruitment : 6 month Duration Treatment : 12 week Duration follow-up : 36 week Anticipated Start Date / Anticipated End Date : November 2015 - October 2016 Target Population /Demographics : Patients &gt; 18 year , live chronic hepatitis C genotype 1 , 2 4 , West Central Africa . In genotype group approx . 50 % patient HCV-HIV co-infected , 50 % patient mono-infected HCV This study enable u assess feasibility , tolerance efficacy strategy resource-constrained setting considerable treatment need .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Antiviral Agents</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<mesh_term>Ledipasvir</mesh_term>
	<mesh_term>Ledipasvir , sofosbuvir drug combination</mesh_term>
	<criteria>Age≥18 year Confirmed G1 , G2 G4 HCV infection Plasma HCVRNA ≥1000 IU/mL No history HCV treatment kind Willingness use birth control method ( hormonal intrauterine device woman , condom men ) , start HCV treatment initiation continue 4months ( woman ) 7 month ( men ) end treatment . Weight ≥40 kg ≤125 kg For patient infected HIV : Confirmed HIV1 infection Stable HIV treatment least 8 week two NRTIs ( tenofovir abacavir , lamivudine emtricitabine ) third agent ( raltegravir , lopinavir/ritonavir , atazanavir/ritonavir , darunavir/ritonavir , efavirenz , nevirapine ) Current CD4+ lymphocytes count ≥100/mm3 Current plasma HIV1 RNA &lt; 200 copies/mL For patient : Cirrhosis classify ChildPugh B C Coinfection Hepatitis B virus Pregnant breastfeed ongoing History transplantation organ tissue Progressive Cancer , include hepatocellular carcinoma Epilepsy Sickle Cell Disease A history myocardial infarction severe heart disease Excessive consumption alcohol drug user , absence substitution methadone , stable wean three month require Ongoing Participation another clinical trial Contraindications Sofosbuvir define Summary Product Characteristics At least one follow laboratory abnormality : Haemoglobin &lt; 10 g / 100 ml ( woman ) &lt; 11 g / 100 ml ( man ) Platelet count &lt; 50,000 / mm3 polymorphonuclear neutrophils rate &lt; 750 / mm3 Creatinine clearance &lt; 50ml / min For patient infected HIV : Severe opportunistic infection last 6 month Poor adherence antiretroviral treatment history Use antiretroviral drug permit test</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Africa</keyword>
	<keyword>Hepatitis C</keyword>
	<keyword>HIV</keyword>
	<keyword>Antiviral treatment</keyword>
	<keyword>Adults</keyword>
	<keyword>HCV genotype 1</keyword>
	<keyword>HCV genotype 2</keyword>
	<keyword>HCV genotype 4</keyword>
</DOC>